top of page
GenFlare---Logo.png

Filter by:

Clear Filters

You might also like:

Episode 8: Launching Lumara

Episode 8: Launching Lumara

Episode 8 brings the series together with a pragmatic launch integration plan: how a specialty biologic turns strategy into day-one execution. We outline the success factors that consistently separate winners: clear, payer-oriented messaging; layered evidence with early RWE; real-time competitive response; cross-TA access innovation; and tight alignment across Access, HEOR, Medical, and Field.

More
Episode 7: Lessons from Elsewhere –– What Other TAs Are Doing Better

Episode 7: Lessons from Elsewhere –– What Other TAs Are Doing Better

Episode 7 looks outside severe asthma to borrow what works in oncology, migraine, and rare disease—and translate those access innovations to Lumara’s launch.

More
Episode 6: The Unknown Unknowns

Episode 6: The Unknown Unknowns

Episode 6 pulls back the curtain on competitive intelligence (CI) maturity in severe asthma launches—what top teams track, how fast they learn, and why it matters for pricing, access, messaging, and patient support. We contrast integrated, always-on CI programs with reactive, vendor-only approaches, and show how social listening, field feedback loops, KOL digital patterns, and payer advisory monitoring translate into real decisions.

More
Episode 5: Scaling the Access Wall

Episode 5: Scaling the Access Wall

Episode 5 examines how real-world evidence (RWE) is now the currency of access decisions. Beyond trials, payers want proof in routine care—on exacerbations, persistence, and healthcare utilization—and they use it for formulary positioning and renewal negotiations.

More
Episode 4: Message Battles

Episode 4: Message Battles

In Episode 4 we'll explore how existing brands in the Severe Asthma market are positioning their value stories to payers — in both economic and clinical terms. The episode will examine the structure, tone, and content of competitor access messaging, including AMCP dossiers, value decks, and in-field conversations. Lumara’s team must develop a differentiated and credible payer narrative — one that can cut through entrenched positioning and resonate with pharmacy and medical directors.

More
Episode 3: Patient Support Showdown

Episode 3: Patient Support Showdown

Episode 3 zeroes in on the first-fill moment and early adherence—where HUB design, copay policy, and specialty-pharmacy handoffs can make or break momentum. We unpack the essentials of high-performing programs (benefits investigation, real-time PA tracking, FRM support, nurse case management, and digital enrollment) and spotlight where patients and offices most often stall.

More
Lumara Series Episode 2: The Coverage Chessboard

Lumara Series Episode 2: The Coverage Chessboard

Episode 2 dives into the real engine of access: how plans decide who gets preferred, who gets blocked, and what it really costs to move tiers.

More
Lumara Series Episode 1: Meet Lumara

Lumara Series Episode 1: Meet Lumara

In Episode 1, we introduce Lumara—a fictional, once-monthly biologic with dual IL-5 and IL-13 inhibition—poised to enter a crowded severe-asthma market.

More
Trailer: The Lumara Series

Trailer: The Lumara Series

Series Overview: The Lumara Series is an 8-episode, TA-specific competitive intelligence podcast produced by Genflare using commercially...

More
What Airbnb’s AI-First Pivot Means for Specialty Pharma

What Airbnb’s AI-First Pivot Means for Specialty Pharma

The seamless, AI-powered experiences consumers encounter in travel, retail, and entertainment shape their expectations of what healthcare support should feel like.

More
How AI Voice Technology Reshaped Publishing—and What It Means for Pharma.

How AI Voice Technology Reshaped Publishing—and What It Means for Pharma.

Turning Up the Volume: How AI Voice Technology Reshaped Publishing—and What It Means for Other Industries Artificial intelligence is now...

More
Breaking Down Barriers: Why Pharma Must Simplify Eligibility Criteria

Breaking Down Barriers: Why Pharma Must Simplify Eligibility Criteria

Patients facing cancer, autoimmune disease, or rare disorders don’t have time to spare—but too often, the very first step in their...

More
From Chatbots to Co-Pilots — Why Pharma Needs Agentic AI

From Chatbots to Co-Pilots — Why Pharma Needs Agentic AI

What if your most consistent team member never got tired, forgot nothing, escalated wisely, and worked 24/7 without complaint?

More

Lumara Series Episode 1: Meet Lumara

  • Writer: Greg Johnsen
    Greg Johnsen
  • Oct 1, 2025
  • 1 min read

Meet Lumara: A New Contender in Severe Asthma


In Episode 1, we introduce Lumara—a fictional, once-monthly biologic with dual IL-5 and IL-13 inhibition—poised to enter a crowded severe-asthma market. With launch roughly 12 months out, early conversations with payers and providers have begun, and the competitive set—Dupixent, Fasenra, Tezspire, Nucala—is well established. We frame the stakes, surface emerging access vulnerabilities, and set the tone for an eight-part, intelligence-driven series built for time-constrained market access and brand leaders.


What you’ll learn

  • The current access landscape for specialty meds in severe asthma

  • Typical launch challenges for new entrants in entrenched TAs

  • Why Lumara represents a realistic, high-stakes competitor

  • The competitive-intelligence themes we’ll unpack across the series


Featured segments

  • Three Strategic Questions Every Entrant Must Answer

  • What the Market Looks Like Today — quick stats and payer trends

  • In the Shoes of a Payer — early positioning challenges for Lumara


About the series & how it was madeThe Lumara Series is both an educational flyover of biologic commercialization and a live demo of what consumer-grade GenAI tools can produce—fast and affordably. Imperfections aside, the direction is transformative. Genflare acts as your CI partner, connecting dots and translating signals into action.

 
 
 

Recent Posts

Comments

bottom of page